Skip to main content
SpringerLink
Log in

miR-205-3p Functions as a Tumor Suppressor in Ovarian Carcinoma

  • Original Article
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Ovarian cancer (OC) represents the most lethal form of gynaecologic cancers in developed countries. To develop a better therapeutic against OC, characterizing new classes of molecular regulators such as microRNAs (miRNAs) involved in OC tumorigenesis becomes immensely important. We used human OC cell lines to study the expression pattern of miRNA-205-3p. We then employed miRNA-205-3p mimic and inhibitor to elucidate its functional role in OC cells. Downstream target of miRNA-205-3p was characterized in OC cells with luciferase gene reporter assay and Western blotting. Its functional role in OC was also investigated with the siRNA approach. Lastly, we assessed the expression change of miRNA-205-3p and its newly identified target in human OC tissues. miR-205-3p was downregulated in five human OC lines tested. Over-expressing miR-205-3p reduced OC cell proliferation and migration. MAPK10 was identified as a direct target of miR-205-3p. Knocking down MAPK10 suppressed OC cell growth and migration. In contrast, knocking down miR-205-3p promoted clonogenicity of primary ovary cells. In clinical samples, miR-205-3p and MAPK10 expressed inversely in accordance with their expression patterns in OC cells. miR-205-3p was shown as a novel tumor suppressor in OC via inhibiting the MAPK10 pathway. This new finding may inspire new personalized treatment for OC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur J Cancer Prev. 2001;10:125–9.

    Article  Google Scholar 

  2. La Vecchia C. Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev. 2017;26:55–62.

    Article  Google Scholar 

  3. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415–28.

    Article  CAS  Google Scholar 

  4. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29.

    Article  CAS  Google Scholar 

  5. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl). 2006;84:16–28.

    Article  Google Scholar 

  6. Romero I, Bast RC Jr. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012;153:1593–602.

    Article  CAS  Google Scholar 

  7. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.

    Article  CAS  Google Scholar 

  8. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–707.

    Article  CAS  Google Scholar 

  9. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13–21.

    Article  CAS  Google Scholar 

  10. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42:D68–73.

    Article  CAS  Google Scholar 

  11. Bogoyevitch MA, Boehm I, Oakley A, et al. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim Biophys Acta. 1697;2004:89–101.

    Google Scholar 

  12. Kinose Y, Sawada K, Nakamura K, et al. The role of microRNAs in ovarian cancer. Biomed Res Int. 2014;2014:249393.

    Article  Google Scholar 

  13. Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008;14:2690–5.

    Article  CAS  Google Scholar 

  14. Wyman SK, Parkin RK, Mitchell PS, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One. 2009;4:e5311.

    Article  Google Scholar 

  15. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425–33.

    Article  CAS  Google Scholar 

  16. Samuel P, Pink RC, Caley DP, et al. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells. Tumour Biol. 2016;37:2565–73.

    Article  CAS  Google Scholar 

  17. Qin AY, Zhang XW, Liu L, et al. MiR-205 in cancer: an angel or a devil? Eur J Cell Biol. 2013;92:54–60.

    Article  CAS  Google Scholar 

  18. Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009;19:439–48.

    Article  CAS  Google Scholar 

  19. Xie H, Zhao Y, Caramuta S, et al. miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS One. 2012;7:e46990.

    Article  CAS  Google Scholar 

  20. Andaur R, Tapia JC, Moreno J, et al. Differential miRNA expression profiling reveals miR-205-3p to be a potential radiosensitizer for low- dose ionizing radiation in DLD-1 cells. Oncotarget. 2018;9:26387–405.

    Article  Google Scholar 

  21. Jiang M, Zhang P, Hu G, et al. Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients. Mol Cell Biochem. 2013;383:67–75.

    Article  CAS  Google Scholar 

  22. Mabuchi S, Altomare DA, Connolly DC, et al. RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 2007;67:2408–13.

    Article  CAS  Google Scholar 

  23. Kumar A, Singh UK, Kini SG, et al. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases. Future Med Chem. 2015;7:2065–86.

    Article  CAS  Google Scholar 

  24. Dai F, Zhang Y, Chen Y. Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. Hum Pathol. 2014;45:1285–93.

    Article  CAS  Google Scholar 

  25. Yang X, Xiang X, Xia M, et al. Inhibition of JNK3 promotes apoptosis induced by BH3 mimetic S1 in chemoresistant human ovarian cancer cells. Anat Rec (Hoboken). 2015;298:386–95.

    Article  CAS  Google Scholar 

  26. Gao S, Jin L, Liu G, et al. Overexpression of RASD1 inhibits glioma cell migration/invasion and inactivates the AKT/mTOR signaling pathway. Sci Rep. 2017;7:3202.

    Article  Google Scholar 

  27. Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol. 2014;171:24–37.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Heze Municipal Hospital, No. 28888 Caozhou Road, Heze, 274000, Shandong, China

    Baohua Qiao, Qingzhi Wang, Yuying Zhao & Jingli Wu

Authors
  1. Baohua Qiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qingzhi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuying Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jingli Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jingli Wu.

Ethics declarations

Clinical evaluation of miR-205-3p and MAPK10 gene expression in human OC tissues was approved by hospital ethical committee (#HZMH-076-jk). A total of 20 cancer patients were enrolled and the informed consent was obtained.

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 600 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qiao, B., Wang, Q., Zhao, Y. et al. miR-205-3p Functions as a Tumor Suppressor in Ovarian Carcinoma. Reprod. Sci. 27, 380–388 (2020). https://doi.org/10.1007/s43032-019-00047-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43032-019-00047-y

Keywords

Search

Navigation